Abbott to double down on Dx business; Hospital saves major money by eliminating unneeded cardiac biomarker testing;

> Abbott Laboratories ($ABT) is doubling down even more on its diagnostics and devices business, with plans to sell its generics portfolio for $5.3 billion. Story

> C2N Diagnostics has expanded its partnership with the Washington University School of Medicine in St. Louis focused on developing a blood test that spots Alzheimer's disease at its earliest stages. Release

> Transplant Genomics in Brookline, MA, said it has gained an exclusive license to patents co-owned by Northwestern University and the Scripps Research Institute that form the basis of diagnostic tests to improve how organ transplant patients are managed. Release

> An Ohio diagnostics laboratory is readying for new growth thanks to its iPad app that serves as a pathology reference tool. Story

> Researchers have developed a plasmonic chip for biomarker discovery and the diagnosis of Type 1 diabetes. Abstract

> A hospital said it saved $1.25 million in one year after eliminating unneeded cardiac biomarker testing for acute coronary syndrome. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.